This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor: The recent article by Pegoraro et al. [1] addresses the importance of understanding the relationship between X-chromosome inactivation patterns and phenotypic expression of myopathy in females heterozygous for dystrophin gene mutations. The authors make two major observations reported in this and in a previous article [2] that deserve emphasis: (1) a highly skewed pattern of X-inactivation occurs in blood cells of female patients moderately to severely symptomatic with Duchenne muscular dystrophy (DMD) (although less skewing is apparent in the surviving muscle) and (2) skewing of X-inactivation may not be seen in asymptomatic or mildly affected DMD carriers.
The authors argue indirectly from their data that a significant expansion of the nuclear domain of dystrophin (so-called ``biochemical normalization,'' occurring presumably by diffusion of protein away from myonuclei expressing the normal allele) is an important mechanism by which myofiber integrity can be preserved, despite overall reduction of dystrophin levels. We demonstrated the importance of such a mechanism directly in female mdx mice, which show a progressive decrease in numbers of dystrophin negative fiber segments between 10 and 60 days of age even after gamma-irradiation of muscle incapacitates satellite cells, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
